866-997-4948 (US-Canada Toll Free)

Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains

Published By :

GBI Research

Published Date : 2013-10-31

Category :

Therapeutic Area

No. of Pages : N/A

Product Synopsis

GBI Research has released its research, “ Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains”, which provides in-depth insights into the macular degeneration market forecast until 2019 for the Asia-Pacific (APAC) region covering the four countries of Australia, China, India and Japan. It also covers disease epidemiology; treatment algorithms; treatment patterns; an in-depth analysis of clinical trials including failure rate analysis, pipeline analysis; and an analysis of deals relevant to macular degeneration. Apart from these the report also includes a heat map for the macular degeneration marketed products.  GBI Research analysis shows that the APAC ophthalmology market... Read More

Table Of Content

Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Macular Degeneration Asia-Pacific Market to 2019 – Introduction
2.1 Symptoms
2.2 Etiology
2.3 Pathophysiology
2.3.1 Disease Initiation
2.3.2 Disease Propagation
2.4 Classification
2.4.1 Early AMD
2.4.2 Intermediate AMD
2.4.3 Advanced AMD
2.5 Co-morbidities and Complications
2.6 Diagnosis
2.6.1 History
2.6.2 Examination
2.6.3 Diagnostic Tests
2.7 Epidemiology
2.8 Prognosis and Disease Staging
2.9 Treatment Options
2.9.1 Pharmacological
2.9.2 Treatment Algorithms and Prescribing Habits
2.9.3 Non-pharmacological Care

3 Macular Degeneration Asia-Pacific Market to 2019 – Marketed Products
3.1 Therapeutic Landscape
3.1.1 Lucentis (ranibizumab) – Novartis AG/Roche (Genentech)
3.1.2 Eylea (aflibercept) – Regeneron Pharmaceuticals/Bayer Healthcare
3.1.3 Avastin (bevacizumab) – Genentech (Roche)
3.1.4 Macugen (pegaptanib sodium) – Valeant Pharmaceuticals/Pfizer
3.1.5 Visudyne (verteporfin injection) – Novartis AG
3.1.6 Triamcinolone Acetonide
3.2 Comparative Efficacy and Safety

4 Macular Degeneration Asia-Pacific Market to 2019 – Pipeline for Disease
4.1 Overall Pipeline
4.2 Pipeline Analysis by Molecule Type
4.3 Pipeline Analysis by Mechanism of Action
4.4 Clinical Trials
4.4.1 Failure Rate
4.4.2 Clinical Trial Duration
4.4.3 Clinical Trial Size
4.5 Promising Drug Candidates in the Pipeline
4.5.1 MC-1101 – MacuCLEAR, Inc.
4.5.2 KH902 (Fumintide) – Chengdu Kanghong Pharmaceuticals Group Co., Ltd.

5 Macular Degeneration Asia-Pacific Market to 2019 – Market Forecast to 2019
5.1 Geographical Markets
5.1.1 APAC Market
5.1.2 Australia
5.1.3 China
5.1.4 India
5.1.5 Japan
5.2 Drivers and Barriers for the Disease Market
5.2.1 Drivers
5.2.2 Barriers

6 Macular Degeneration Asia-Pacific Market to 2019 – Deals and Strategic Consolidations
6.1 Deals Analysis
6.2 Major Co-development Deals
6.2.1 Sinphar Enters into Co-development Agreement with MacuCLEAR
6.2.2 Allergan Enters into Co-development Agreement with Molecular Partners
6.2.3 X-Body BioSciences Enters into Co-development Agreement with Hengrui Medicine for AMD
6.2.4 Alcon Enters into Collaboration with AstraZeneca
6.2.5 Acucela Enters into Co-Development Agreement with Otsuka Pharma for ACU-4429
6.3 Major Licensing Deals
6.3.1 Allegro Ophthalmics Enters into Licensing Agreement with Senju Pharma to Develop Integrin Peptide Therapy
6.3.2 Allergan Enters into Licensing Agreement with Molecular Partners
6.3.3 PanOptica Enters into Licensing Agreement with OSI Pharma
6.3.4 Lpath Enters into Licensing Agreement with Pfizer
6.3.5 Shionogi Enters into Licensing Agreement with OncoTherapy Science

7 Macular Degeneration Asia-Pacific Market to 2019 – Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 IND-filed and Phase 0
7.1.4 Phase I
7.1.5 Phase II
7.1.6 Phase III
7.1.7 Undisclosed
7.2 Market Forecasts to 2019
7.2.1 Asia-Pacific
7.2.2 Australia
7.2.3 China
7.2.4 India
7.2.5 Japan
7.3 Market Definitions
7.4 Abbreviations
7.5 References
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Primary Research
7.6.4 Therapeutic Landscape
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer

List of Tables


Table 1: Macular Degeneration Market, Classification of AMD
Table 2: Macular Degeneration Market, Treatment Recommendations and Follow-up for Non-neovascular AMD
Table 3: Macular Degeneration Market, Treatment Recommendations and Follow-up for Neovascular AMD
Table 4: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Discovery), 2013
Table 5: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Preclinical), 2013
Table 6: Macular Degeneration Market, Global, Pharmaceutical Pipeline (IND/CTA-filed), 2013
Table 7: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase I), 2013
Table 8: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase II), 2013
Table 9: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase III), 2013
Table 10: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Undisclosed), 2013
Table 11: Macular Degeneration Market, Asia-Pacific, Market Forecast, 2012–2019
Table 12: Macular Degeneration Market, Australia, Market Forecast, 2012–2019
Table 13: Macular Degeneration Market, China, Market Forecast, 2012–2019
Table 14: Macular Degeneration Market, India, Market Forecast, 2012–2019
Table 15: Macular Degeneration Market, Japan, Market Forecast, 2012–2019

List of Figures


Figure 1: Macular Degeneration Market, Pathophysiology of AMD
Figure 2: Macular Degeneration Market, Types of Dry AMD
Figure 3: Macular Degeneration Market, Classification of AMD
Figure 4: Macular Degeneration Market, Amsler Grid Test
Figure 5: Macular Degeneration Market, Asia-Pacific, Epidemiology, 2012–2019
Figure 6: Macular Degeneration Market, Photodynamic Therapy
Figure 7: Macular Degeneration Market, Treatment Algorithm by Type and by Stage
Figure 8: Macular Degeneration Market, Fluorescein Angiogram Showing Laser Photocoagulation Images
Figure 9: Macular Degeneration Market, Global, Annual Sales ($m), 2012
Figure 10: Macular Degeneration Market, Lucentis, Global, Annual Sales ($m), 2006–2012
Figure 11: Macular Degeneration Market, Eylea, Global, Annual Sales ($m), 2011–2012
Figure 12: Macular Degeneration Market, Visudyne, Global, Annual Sales ($m), 2005–2012
Figure 13: Macular Degeneration, Global, Heat Map of Safety and Efficacy for Marketed Products
Figure 14: Macular Degeneration Market, Global, Pipeline, 2013
Figure 15: Macular Degeneration Market, Global, Pipeline, 2013
Figure 16: Macular Degeneration Market, Global, Pipeline, 2013
Figure 17: Macular Degeneration Market, Global, Clinical Trial Failure Rate, 2013
Figure 18: Macular Degeneration Market, Global, Pipeline, Clinical Trial Duration, 2013
Figure 19: Macular Degeneration Market, Global, Pipeline, Clinical Trial Size, 2013
Figure 20: Macular Degeneration Market, Global, Annual Sales ($bn), 2012–2019
Figure 21: Macular Degeneration Market, Australia, Annual Sales ($m), 2012–2019
Figure 22: Macular Degeneration Market, China, Annual Sales ($m), 2012–2019
Figure 23: Macular Degeneration Market, India, Annual Sales ($m), 2012–2019
Figure 24: Macular Degeneration Market, Japan, Annual Sales ($m), 2012–2019
Figure 25: Macular Degeneration Market, Global, Deals, 2007–2013
Figure 26: Macular Degeneration Market, Global, Co-development Deals, 2007–2013
Figure 27: Macular Degeneration Market, Global, Licensing Deals, 2007–2013
Figure 28: GBI Research Market Forecasting Model

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Cardiovascular Information System Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

    By - Transparency

    The cardiovascular information system (CVIS) is a web-based collection of clinical information and research material software architecture that facilitates decision support, information exchange and scientific advancement of the cardiovascular field. The aim of this CVIS is to endorse an advanced level of evidence-based professional standards in cardiac rehabilitation. CVIS is a data driven patient informatics integrated hemodynamic system that can store all the information related to cardiovascular disease patient. All the information is stored in CVIS for efficient recording and...

  • Psychiatry Therapies Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020

    By - Transparency

    Psychiatric therapies include therapeutic interaction processes between trained psychiatric professionals and the patient in order to treat psychology related problems of patients. Psychiatric therapies involve the treatment of emotional and mental disorders and behavior disturbance by using psychological techniques and therapies. These psychiatry therapies are designed to change the behavior of a patient and provide relief from the disorder.  Psychiatry therapies basically rely on establishing relationship between patients and psychiatry therapist for developing...

  • Medical Laboratories Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020

    By - Transparency

    Medical laboratories are defined as the independent, commercial enterprises that provide information to the healthcare professionals about the severity, onset and reason of patients' physical ailments. Medical laboratories include biological, bacteriological, histological, pathological and chemical analysis, urinalysis and dental and medical X-rays. About 70% of the health care decisions taken by doctors for treatment of diseases are based on the results of laboratory testing which makes the medical laboratories a vital part of the global healthcare system. Based on the testing...